NEW YORK, May 24, 2016 /PRNewswire/ -- Pomerantz LLP is
investigating claims on behalf of investors of XenoPort Inc.
("XenoPort" or the "Company") (NASDAQ: XNPT) (ISIN:
US98411C100) (CUSIP: 98411C10) concerning the proposed acquisition
of XenoPort by Arbor Pharmaceuticals, LLC.
XenoPort shareholders seeking more information about this
acquisition are advised to contact Robert
Willoughby at rswilloughby@pomlaw.com or 212-661-1100 or
888-476-6529, ext. 9980.
The investigation concerns whether the XenoPort directors are
breaching their fiduciary duties by failing to adequately maximize
shareholder value. Under the terms of the proposed
transaction, XenoPort shareholders will be entitled to receive
$7.03 in cash for each share of
XenoPort common stock held.
However, an analyst recently set a target price of $10.00 per share. Moreover, Total Revenue is
below the average of comparable transactions, according to a
Bloomberg analysis.
Pomerantz LLP, with offices in New
York, Chicago, Florida, and Los
Angeles, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz LLP pioneered the field of securities class actions.
Today, more than 80 years later, the Pomerantz LLP continues in the
tradition he established, fighting for the rights of the victims of
securities fraud, breaches of fiduciary duty, and corporate
misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of defrauded investors. See
www.pomerantzlaw.com.
CONTACT:
Robert
Willoughby
Pomerantz LLP
212-661-1100 ext. 9980
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-llp-investigates-claims-that-the-merger-may-not-be-in-the-best-interest-of-investors-of-xenoport-inc---xnpt-300274051.html
SOURCE Pomerantz LLP